We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

80 hedge funds and large institutions have $314M invested in Cymabay Therapeutics in 2017 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 20 increasing their positions, 18 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

166% more call options, than puts

Call options by funds: $393K | Put options by funds: $148K

160% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 10

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

28% more capital invested

Capital invested by funds: $244M → $314M (+$69.4M)

25% more funds holding

Funds holding: 64 → 80 (+16)

11% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 18

Holders
80
Holders Change
+16
Holders Change %
+25%
% of All Funds
1.81%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
26
Increased
20
Reduced
18
Closed
10
Calls
$393K
Puts
$148K
Net Calls
+$245K
Net Calls Change
-$31K

Top Buyers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
+$9.4M
2
UBS AM
UBS AM
Illinois
+$5.04M
3
NC
Nexthera Capital
New York
+$4.46M
4
AAP
Ardsley Advisory Partners
Connecticut
+$3.67M
5
RG
Redmile Group
California
+$3.04M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$14M
2
CAM
Cormorant Asset Management
Massachusetts
-$4.03M
3
A
Abingworth
United Kingdom
-$3.38M
4
Renaissance Technologies
Renaissance Technologies
New York
-$3.21M
5
Deutsche Bank
Deutsche Bank
Germany
-$2.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
MCM
51
Moore Capital Management
New York
$460K – – –
State Street
52
State Street
Massachusetts
$409K +$83.9K +9,822 +28%
VEA
53
Virtus ETF Advisers
New York
$391K +$363K +42,485 New
VFA
54
Virtus Fund Advisers
Connecticut
$391K +$363K +42,485 New
Wells Fargo
55
Wells Fargo
California
$360K +$330K +38,646 +7,729%
AGM
56
Alpine Global Management
New York
$311K +$289K +33,797 New
CS
57
Credit Suisse
Switzerland
$271K +$116K +13,593 +86%
SPC
58
Sigma Planning Corp
Michigan
$251K +$105K +12,300 +82%
WMSA
59
Weiss Multi-Strategy Advisers
New York
$230K +$214K +25,000 New
VF
60
Virtu Financial
New York
$228K +$76K +8,899 +56%
TI
61
Trexquant Investment
Connecticut
$207K +$192K +22,511 New
Goldman Sachs
62
Goldman Sachs
New York
$197K +$183K +21,407 New
LCM
63
LVM Capital Management
Michigan
$193K – – –
EMG
64
Ellington Management Group
Connecticut
$190K -$74.3K -8,700 -30%
ARTA
65
A.R.T. Advisors
New York
$140K +$130K +15,231 New
Two Sigma Advisers
66
Two Sigma Advisers
New York
$134K +$6.84K +800 +6%
Charles Schwab
67
Charles Schwab
California
$115K +$107K +12,465 New
DS
68
DRW Securities
Illinois
$110K -$68.4K -8,000 -40%
UBS Group
69
UBS Group
Switzerland
$80K +$48.5K +5,670 +189%
IA
70
IFP Advisors
Florida
$46K – – –
TRCT
71
Tower Research Capital (TRC)
New York
$25K -$19K -2,227 -45%
DCM
72
Delpha Capital Management
New York
$22K +$20.1K +2,350 New
LTFS
73
Ladenburg Thalmann Financial Services
Florida
$16K – – –
Parallax Volatility Advisers
74
Parallax Volatility Advisers
California
$14K – – –
PSC
75
Piper Sandler & Co
Minnesota
$7K +$6.84K +800 New
1 2
3
4

CBAY Hedge Fund Activity: Q4 2017 in Review

80 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2017, worth a combined $314M — up 28% from $244M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new CBAY positions and 10 closed out — a net gain of 16 holders — while 20 added to existing stakes and 18 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $9.4M. The largest seller was Millennium Management, cutting an estimated $14M.

  • 80 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2017, up from 64 in Q3 2017.
  • Funds reported $314M of Cymabay Therapeutics stock for Q4 2017, up 28% quarter-over-quarter.
  • 26 funds opened new Cymabay Therapeutics positions in Q4 2017 and 10 closed out, a net change of +16 holders.
  • The largest Cymabay Therapeutics buyer in Q4 2017 was Farallon Capital Management, an estimated $9.4M added.
  • The largest Cymabay Therapeutics seller in Q4 2017 was Millennium Management, an estimated $14M sold.

Based on aggregated 13F filings for Q4 2017.